Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + Zanzalintinib in Advanced RCC
NCT07489495Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Primary completion
- Nov 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Belzutifan + Zanzalintinib with Belzutifan + Placebo (2 arms). Primary endpoints: Progression-free Survival at 30 months and Overall Survival at 50 months. Started Apr 2026; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07489495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489495.